Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.
Plasminogen activator inhibitor type-1 (PAI-1) is a rapid inhibitor of tissue plasminogen activator (tPA) in circulation. Evidence suggests that the PAI-1 concentration is responsible for the regulation of the endogenous fibrinolytic system through its tPA/PAI-1 interactions. Accordingly, increased levels of PAI-1 have emerged as a masker for an increased thrombolic risk. This article represents a status report of mechanism of action, regulation of plasma levels, as well as the role of PAI-1 in arterial and venous thromboembolic disease.
Huber
K
K
Department of Cardiology, University of Vienna-General Hospital, Währinger Gürtel 18/20, A-1090 Vienna, Austria. kurt.huber@univie.ac.at
D000818:Animals; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000235:genetics / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000235:genetics / Q000502:physiology; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000503:physiopathology*
D017395:Plasminogen Activator Inhibitor 1